|
Video: What is a Stock Split?
|
|
Kazia Therapeutics is an oncology-focused biotechnology company that has a portfolio of development candidates in a range of oncology indications. Co.'s primary development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase/Akt/mTor pathway, that is being developed as a potential therapy for glioblastoma as well as other forms of brain cancer. Paxalisib is orally administered and is presented in a 15mg capsule formulation. Co.'s second development candidate is EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. EVT801 selectively targets lymphangiogenesis, the formation of new lymphatic vessels. According to our Kazia Therapeutics stock split history records, Kazia Therapeutics has had 1 split. | |
|
Kazia Therapeutics (KZIA) has 1 split in our Kazia Therapeutics stock split history database. The split for KZIA took place on July 14, 2017. This was a 1 for 4 reverse split, meaning for each 4 shares of KZIA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.
When a company such as Kazia Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Kazia Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Kazia Therapeutics shares, starting with a $10,000 purchase of KZIA, presented on a split-history-adjusted basis factoring in the complete Kazia Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/28/2014 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$15.96 |
|
End price/share: |
$0.39 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-97.56% |
|
Average Annual Total Return: |
-31.01% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$244.51 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
07/14/2017 | 1 for 4 |
|
|